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Abstract
Background: In yeast, DNA damage leads to the mono and polyubiquitination of the sliding clamp
PCNA. Monoubiquitination of PCNA is controlled by RAD18 (E3 ligase) and RAD6 (E2 conjugating
enzyme), while the extension of the monoubiquitinated PCNA into a polyubiquitinated substrate
is governed by RAD5, and the heterodimer of UBC13/MMS2. Each modification directs a different
branch of the DNA damage tolerance pathway (DDT). While PCNA monoubiquitination leads to
error-prone bypass via TLS, biochemical studies have identified MMS2 along with its heteromeric
partner UBC13 to govern the error-free repair of DNA lesions by catalyzing the formation of lysine
63-linked polyubiquitin chains (K63-polyUb). Recently, it was shown that PCNA polyubiquitination
is conserved in human cells and that this modification is dependent on RAD18, UBC13 and SHPRH.
However, the role of hMMS2 in this process was not specifically addressed.
Results: In this report we show that mammalian cells in which MMS2 was reduced by siRNA-
mediated knockdown maintains PCNA polyubiquitination while a knockdown of RAD18 or UBC13
abrogates PCNA ubiquitination. Moreover, the additional knockdown of a UEV1A (MMS2
homolog) does not deplete PCNA polyubiquitination. Finally, mouse embryonic stem cells null for
MMS2 with or without the additional depletion of mUEV1A continue to polyubiquitinated PCNA
with normal kinetics.
Conclusion: Our results point to a high level of redundancy in the DDT pathway and suggest the
existence of another hMMS2 variant (hMMSv) or complex that can compensate for its loss.
Background
Protecting the integrity of the DNA genome is important
for the long-term survival of higher eukaryotes [1]. Given
the importance of genomic integrity, it is not surprising
that an elaborate system of cell cycle checkpoints and
DNA repair systems has evolved in higher vertebrates.
However, the failure to remove DNA lesions in a timely
and efficient manner often forces a cell to bypass the dam-
age in order to avoid replication stalling. This is accom-
plished through DNA damage tolerance (DDT), an
important component of the DNA damage response. DDT
allows replication machinery stalled at sites of DNA dam-
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age to continue with DNA synthesis by allowing bypass of
such sites in either an error-prone or error-free manner
[2]. The control of such a pathway is dependent on the
modification status of the sliding clamp PCNA.
In the absence of DNA damage, yeast PCNA is typically
sumoylated on K164 which promotes normal S phase
progression by preventing unwanted recombination,
while replication stress results in PCNA ubiquitination on
the same lysine residue [3,4]. There is a central role for
Rad6 (ubiquitin conjugating E2 enzyme) and Rad18
ubiquitin ligase (E3 ligase) in PCNA ubiquitination. Dur-
ing genotoxic stress, Rad6 is recruited by Rad18 to sites of
DNA damage where it monoubiquitinates PCNA [4].
Monoubiquitinated PCNA facilitates the recruitment of
error-prone translesion polymerases including polymer-
ase η, and Rev1 [5,6]. While undesirable, the mutations
induced by this error-prone mechanism may be less dele-
terious than catastrophic blockage of replication forks.
However, there is also an alternate complex (Ubc13/
Mms2/Rad5) that forms and mediates error-free bypass
by extending the monoubiquitinated PCNA via K63-poly-
ubiquitin chains [4]. The outcome of this polyubiquitina-
tion has yet to be fully elucidated; it clearly does not
involve the proteasome but more likely involves fork
reversal, recombination with an undamaged sister chro-
matid either at or behind the replication fork [4,7].
A majority of the genes of the DDT pathway have been
conserved from yeast to human including RAD18, RAD6,
MMS2, UBC13, PCNA and most of the translesion
polymerases [8,9]. As such, Kannouche et al., and Watan-
abe et al., have shown that the error-prone arm of DDT
involving PCNA monoubiquitination and concordant
polymerase switching is fully conserved in mammalian
cells [10,11]. Recently, we reported that PCNA is polyu-
biquitinated in human cells after DNA damage [12,13].
Accordingly, PCNA polyUb was shown to be dependent
on RAD18 (suggesting that monoubiquitination of PCNA
is required), and also on UBC13 (the ubiquitin conjugase
previously shown to be involved in K63-polyubiquitin
chain formation) [12]. Recently, Motegi et al and Unk et
al. have confirmed the existence of polyubiquitinated
PCNA and have suggested that SHPRH (human ortholog
of yeast RAD5) is the E3 ligase involved this process
[14,15]. However, it has yet to be determined whether
hMMS2 (heteromeric partner of hUBC13) participates
significantly in PCNA polyubiquitination in human cells.
MMS2 is a ubiquitin conjugating enzyme variant (UEV)
protein that resembles ubiquitin conjugating enzymes
(E2s) but lacks a conserved active cysteine site [16]. Based
on this original observation, it was hypothesized that UEV
proteins behaved as negative regulators of ubiquitination.
However, biochemical evidence showed that MMS2
forms a heteromeric complex with UBC13 (an E2 conju-
gating enzyme with active catalytic cysteine site) to cata-
lyze the formation of K63-polyubiquitin chains [17,18].
In addition, loss of MMS2 in yeast resulted in overt sensi-
tivity to a variety of genotoxic agents as well as increased
spontaneous and UV induced mutagenesis confirming its
role in the error-free damage avoidance arm of DDT
[18,19]. Similar to the findings in yeast, the expression of
anti-sense MMS2 in human cells resulted in increased UV
induced mutagenesis [20]. These data provide strong evi-
dence of the importance of MMS2 in the assembly of
polyubiquitin chains linked through K63 in the error free
damage avoidance arm of the DDT pathway in both yeast
and humans.
Since MMS2 serves such an important role in error free
DNA repair in both humans and yeast and has been
shown to be indispensable in yeast PCNA polyubiquitina-
tion, we predicted that it would be equally important in
PCNA ubiquitination in mammalian cells. Therefore, we
examined the state of PCNA ubiquitination in mouse
MMS2 knock-out embryonic stem cells and human cells
in which hMMS2 had been depleted by siRNA. Unlike
budding yeast which has only one UEV gene (Mms2),
human cells contain at least 4 UEV loci. In this paper, we
address the role of hMMS2 and hUEV1a, the most likely
functional orthologues of yeast MMS2, in promoting
PCNA polyubiquitination. We report that PCNA polyu-
biquitination proceeds with normal kinetics in the pres-
ence or absence of MMS2 whereas UBC13 or RAD18
knockdown abrogates PCNA polyubiquitination. Addi-
tionally, depletion of UEV1a does not disrupt PCNA poly-
ubiquitination after DNA damage. This suggests that there
is a high degree of redundancy built into mammalian sys-
tems and the potential for the existence of a MMS2 variant
that can compensate for the loss of hMMS2.
Methods
Cell culture and treatments
The mouse embryonic MMS+/+  or MMS-/-  stem cells
(kindly provided by Dr. Wei Xiao, University of Saskatch-
ewan) were cultured in DMEM supplemented with 15%
FBS, 1X pen/strep, LIF (kindly provided by Dr. M. McBur-
ney, Ottawa Health Research Institute) and beta-mercap-
toethanol (EMD Chemicals, Omnipur, Gibbstown New
Jersey, United States). The HEK 293T and Hela cell lines
were cultured in DMEM (Gibco, Invitrogen, Carlsbad,
California, United States) supplemented with 10% FBS
(Gibco, Invitrogen, Carlsbad, California, United States).
293T and Hela cells were transfected with siGENOME
SMARTpool reagent specific for human RAD18, UBC13,
MMS2 and/or hUEV1a (Dharmacon Research, Lafayette,
Colorodo, United States) using oligofectamine (Invitro-
gen Carlsbad, California, United States). The transfections
were performed 72 hours prior to harvesting the cells toBMC Molecular Biology 2008, 9:24 http://www.biomedcentral.com/1471-2199/9/24
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achieve optimal long-term knockdown as determined by
immunoblotting. UV irradiation (30 J/m2) was performed
on exponentially growing cells using a UVC germicidal
lamp at a fluence rate of 1 J/m2/s.
Western blotting
RNA interference and the preparation of proteins lysates
were performed as described previously [12]. Cells trans-
fected with siGENOME SMARTpool reagent specific for
human UBC13, human RAD18 human MMS2 or human
UEV1A (Dharmacon Research, Lafayette, Colorodo,
United States) were UV irradiated and lysed 6 h post-treat-
ment. Samples were sonicated, soluble fractions were
recovered, and proteins were quantified. Proteins were
resolved on either a one phase or two phase SDS-polyacr-
ylamide gel (10% or 10% and 15%) and electroblotted
onto a Hybond C nitrocellulose membrane (Amersham
Pharmacia Biotech, Piscataway, New Jersey, United
States). The following antibodies were used: mouse mon-
oclonal (mAb2h11) that recognizes both hMMS2 and
UEV1a [21], mouse monoclonal UBC13 (mAb 4E11)
[21], mouse monoclonal PCNA PC10 (Millipore, Chemi-
con, Temecula California), and mouse monoclonal actin
(Sigma, St. Louis Missouri, United States). Proteins were
visualized using SuperSignal West Pico Chemilumines-
cent Substrate (Pierce Biotechnology Rockford, Illinois,
United States).
Immunoprecipitations
PCNA immunoprecipitations were carried out as
described previously [12,13]. Brielfy cells were UV-irradi-
ated with 30 J/m2 as described above and either left
untreated or transfected with SiGenome Smartpool rea-
gent specific for human RAD18, human MMS2 and/or
human UEV1a (Dharmacon). An anti-PCNA antibody
was incubated overnight with 500 μg of protein lysate.
The following day, lysates were incubated with 100 μL of
Gamma-Bound Sepharose Beads (Amersham Pharmacia
Biotech). After 48 h beads were washed extensively in lysis
buffer, and proteins were eluted by boiling in Laemmli's
SDS sample buffer. Immunoblotting was performed as
described above except that the PVDF membranes (Milli-
pore) were used and autoclaved for 20 min in ddH2O
after protein transfer, and proteins were visualized using
chemiluminescent substrate (Amersham Pharmacia).
RNA Extractions
E14K mouse embryonic stem (ES) cells (wild type and
mMms2-/-) were grown on 100 mm tissue culture dishes
coated with 1% gelatin. Cells were cultured at 37°C in a
5% CO2 atmosphere, in cell medium containing high glu-
cose D-MEM (Sigma) supplemented with 15% fetal
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 0.1 mM MEM non-essential amino acids (all from
Invitrogen), 0.05 mM 2-mercaptoethanol (Sigma), and
1,000 U/ml LIF (ESGRO; Chemicon). Prior to total RNA
extraction, cells were trypsinized and collected. The cells
were lysed in Trizol (Invitrogen) and total RNA was iso-
lated using the manufacturer's suggested protocol. Prior to
cDNA synthesis, the RNA samples were DNase I treated
using Ambion's DNA-free kit as per the manufacturer's
suggested protocol. Total RNA (2 μg) was reversed tran-
scribed using oligo(dT)20 and Invitrogen's Thermoscript
RT-PCR system as per the manufacturer's protocol. The
PCR step was subsequently carried out using 2 μl of the RT
reaction, 1.25 μM of each specific primer, and 2.5 U of
Platinum Taq polymerase (Invitrogen) in a 40 μl reaction.
Both mMms2 and β-actin control PCR reactions were
completed under the following conditions: an initial
denaturation at 94°C for 2 minutes, a subsequent dena-
turation step at 94°C for 30 seconds, an annealing tem-
perature of 50°C for 30 seconds, and an extension step at
72°C for 20 seconds. This was repeated for a total of 32
cycles and 26 cycles for mMms2 PCR and β-actin control
PCR respectively, with a final extension of 72°C for 10
minutes. The sequences of the Mms2 forward and reverse
primers are, respectively, 5'-GGCAGTCTCCACAGGAGT-
TAAA-3' and 5'-ACTGGAATTATTGATCCCATTCA-3' to
yield a 283 bp product. The sequences of the β-actin con-
trol PCR forward and reverse primers are 5'-AGGTCAT-
CACTATTGGCAACGA-3' and 5'-
AGTACTTGCGCTCAGGAGGA-3' respectively, to yield a
276 bp product.
Results
Efficient Knockdown of MMS2 and UEV1a
In yeast, monoubiquitination requires the ubiquitin E2/
E3 complex RAD6/RAD18 and further polyubiqutination
is dependent on the RAD5/UBC13/MMS2 complex. In
mammalian cells, RAD18 has been implicated in monou-
biquitination, and SHPRH and UBC13 in polyubiquitina-
tion of PCNA [12,14,15]. To ascertain whether
mammalian MMS2 is also required for polyubiquitina-
tion we targeted MMS2 in HEK 293T and Hela cells using
siRNA (Figure 1). The Mms2 antibody used in our studies
recognizes both Mms2 and the other mammalian
homolog Uev1a [21]. Therefore to confirm effective
knockdown with this antibody we performed a double
knockdown with siRNA targeting both hMMS2 and
hUEV1a. The abundance of MMS2 and UEV1a was found
to be effectively reduced 72 hours post- transfection in
both 293T and Hela cells suggesting that both individual
knockdowns were effective (Figure 1A–C).
PCNA is polyubiquitnated in the absence of MMS2 and/or 
UEV1a
Cells treated with siRNA against MMS2, UEV1a, or both
were exposed to UV light to induce DNA damage and then
assessed for ubiquitination of PCNA. As expected, the
band corresponding to monoubiquitinated PCNA wasBMC Molecular Biology 2008, 9:24 http://www.biomedcentral.com/1471-2199/9/24
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unaffected by MMS2 knockdown after UV irradiation
(Figure 2). Unexpectedly, knockdown of MMS2 alone did
not affect the higher molecular weight bands correspond-
ing to polyubiquitinated PNCA (Figure 2). Since MMS2
belongs to a family of UEVs that have been conserved
throughout evolution in higher eukaryotes [16,22-24] we
speculated that one of these UEVs could compensate for
its loss. Human UEV1A is an obvious candidate since it
can bind to UBC13 and has greater than 90% amino acid
sequence identity with hMMS2 [25]. However, our results
demonstrated little or no reduction in polyubiquitinated
PCNA after knockdown of UEV1a alone or in combina-
tion with MMS2 (Figure 3A and 3B; Additional file 1(A)
and 1(B)). This is in contrast to knockdown of UBC13
(Additional file 2(A) and 2(B)) or RAD18 (Figure 4A and
4B) which effectively blocked PCNA polyubiquitination
(Figure 4A and 4B; Additional file 2(C) and 2(D)). These
findings suggest that MMS2 likely serves a redundant role
in PCNA polyubiquitination.
Abrogation of MMS2 and/or UEV1A does not alter 
ubiquitin laddering
Thus far our immunoblotting data supports the notion
that MMS2 serves a redundant role in PCNA ubiquitina-
tion. However, to confirm that these bands are indeed
ubiquitinated we knocked down MMS2 and UEV1A using
siRNA and performed a PCNA immunoprecipitation fol-
lowed by immunoblotting for ubiquitin. Despite the effi-
cient reduction in MMS2 and UEV1A (Figure 5A and 5C),
several bands corresponding to mono, di, tri and tetra
ubiquitinated species were observed in the double knock-
down lane which was indistinguishable from either of the
single knockdown or the control lane (Figure 5B and 5D
and Additional files 3(A) and 3(B)). Importantly, this lad-
MMS2 Knockdown does not disrupt PCNA polyubiquitina- tion Figure 2
MMS2 Knockdown does not disrupt PCNA polyubiq-
uitination. 293T and Hela cells were transfected with 100 
nM of either control siRNA or siRNA specific for MMS2. 72 
hours later cells were UV irradiated with either 0 or 30 J/m2 
and lysed 6 hours post-treatment followed by immunoblot-
ting with an anti-PCNA antibody.
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siRNA targeting MMS2 and UEV1a results in an efficient  knockdown Figure 1
siRNA targeting MMS2 and UEV1a results in an effi-
cient knockdown. (A) 293T cells were transfected with 
100 nM of either control siRNA, siRNA MMS2 and siRNA 
UEV1A followed by immunoblotting. Cells were lysed at the 
indicated time points and subject to immunoblotting. (B) 
Hela cells were treated as above and lysed 72 hours post-
transfection. (C) 293T cells were treated as in (B).
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dering pattern was similar to the ones observed from pre-
vious studies after treatment with MMS, BPDE or UV light
[12,13,15,26]. Moreover, a knockdown of RAD18 in 293T
cells demonstrates a decreased pattern of polyubiquiti-
nated PCNA as compared to the double knockdown of
MMS2 and UEV1A or cells transfected with control siR-
NAs (Figure 6A and 6B). Finally, PCNA immunoblotting
data (Figure 6B bottom 3 panels) using the same lysates
were consistent with the data obtained from IP's in Figure
5, and figure 6B (upper 2 panels).
MMS2-/- knockout stem cells maintain PCNA 
polyubiquitination
In order to confirm the results of our study in human cells
and rule out the possibility of off target effects of siRNA,
we obtained mouse embryonic stem cells in which the
Mms2 gene had been inactivated by gene targeting. RT-
PCR reactions confirmed the absence of the MMS2 mRNA
(Figure 7A). Interestingly, loss of Mms2  results in an
approximate 50% reduction in the intensity of the MMS2/
UEV1a band detected (Figure 7B). The latter is expected
since the Uev1a levels remain the same and the antibody
recognizes both Mms2 and Uev1a. Monoubiquitination of
PCNA after UV treatment occurred normally and with
identical kinetics in the Mms2-/- cells compared to wild
type. Consistent with our siRNA results in Figures 2, 3, 4,
we did not observe a reduction in PCNA polyubiquitina-
tion in the MMS2 knock-out cells (Figure 7C). Finally,
when we targeted Uev1a in the Mms2-/- cells PCNA ubiq-
uitination was not abrogated (Figure 7D and 7E). In fact
it occurred with normal kinetics as those seen in the
wildtype ES cells and as observed in our human cell lines.
Discussion
UEVs such as MMS2 and UEV1a constitute a highly con-
served family of distinct E2 conjugating enzymes devoid
of a catalytic cysteine [16,20,24]. Functionally they act in
complexes with a heteromeric partner such as UBC13. The
MMS2/UBC13 or UEV1a/UBC13 heterodimer catalyzes
the formation of non-canonical K63-polyubiquitin chains
that are involved in DDT and activation of NF-κB respec-
tively [21]. Since MMS2 has been implicated in the error-
free lesion bypass in yeast and humans and in light of the
recent data demonstrating PCNA polyubiquitination after
DNA damage in human cells [12,15], we sought to deter-
mine whether hMMS2 plays an important role in polyu-
biquitinating PCNA in mammalian cells.
In the present study we demonstrate that cells partially or
totally devoid of MMS2 (through siRNA or gene targeting)
and cells experiencing knockdown of both MMS2 and
UEV1a do not exhibit a significant reduction in PCNA
polyubiquitination after UV irradiation. These results are
in sharp contrast to those obtained from the knockdown
of UBC13 or RAD18. In isolation, the MMS2 findings
might beg the question of whether K63-polyubiquitina-
tion is important in human DNA repair. There are, how-
ever, convincing studies in the recent literature in support
of the importance of hRAD18, hUBC13 and SHPRH (the
human RAD5 homolog) in K63-polyubiquitination of
PCNA and its role in maintaining genomic stability
[12,14,15]. The most parsimonious explanation of our
results would therefore invoke a built in redundancy of
the MMS2 component in the higher eukaryotes.Several
lines of evidence support our contention that redundancy
is the best explanation. First, although hMMS2 was shown
A knockdown of MMS2 and UEV1a does not abrogate PCNA  polyubiquitination Figure 3
A knockdown of MMS2 and UEV1a does not abro-
gate PCNA polyubiquitination. (A) Hela cells were 
treated as in Figure 2 except they were additionally trans-
fected with siRNA UEV1A. (B) 293T cells were treated as in 
Figure 3A.
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to be involved in damage induced mutagenesis, no overt
sensitivity to UV light or increased spontaneous mutagen-
esis was observed in human fibroblasts as it had been
observed in the yeast system [20]. Second, Simpson et al.,
showed that disruption of MMS2 in a chicken cell line, DT
40, did not result in increased sensitivity to DNA damag-
ing agents nor did it promote sister chromatid exchange
[27]. Third, in a previous publication we demonstrated
that knockdown of UBC13 or RAD18 did not entirely
abrogate PCNA ubiquitination [12]. Although this could
be due to incomplete knockdown, recent evidence by
Simpson et al. have demonstrated that RAD18 independ-
ent PCNA ubiquitination occurs in RAD18 null DT40
cells suggesting the presence of compensatory PCNA
ubiquitinating enzyme in higher vertebrates [28]. We
believe this to be the case in human cells as well. Finally,
we show that PCNA is ubiquitinated in the presence or
absence of hMMS2. Overall, these data highlight the
inherent complexity of the DDT pathway and in particular
point to a greater degree of built in redundancy in verte-
brates.
Given the importance of MMS2 in yeast and human cells
and our current finding we asked whether another UEV
gene could complement the loss of hMMS2. To our
knowledge yeast contain only a single UEV locus (MMS2)
while humans contain at least 4 UEV loci including
UBE2V1 (also known as CROC1A, UEV1A, UEV1, CIR1),
UBE2V2 (also known as hMMS2 UEV2, DD-VIT, EDAF-1,
and EDPF-1), TSG101 and UEV3[25,29,30]. UBE2V1 has
RAD18 or UBC13 knockdown disrupts PCNA polyubiquitination Figure 4
RAD18 or UBC13 knockdown disrupts PCNA polyubiquitination. (A) Hela cells were treated the same as in Figure 3 
except that cells were also transfected with siRNA targeting UBC13 and RAD18. (B) 293T cells were treated as in Figure 4B.
siRNA MMS2
UV 30 J/m2
Control siRNA
siRNA UEV1A
A.
siRNA UBC13
siRNA RAD18
+      +      +      +      +     
+
+
+
+ +
+
+
+
+
+ +
+
(Ub)1-PCNA
PCNA 
Actin
Hela
Long 
Expo
Short 
Expo
Polyub
PCNA 
(Ub)1-PCNA
PCNA 
siRNA MMS2
UV 30 J/m2
Control siRNA
siRNA UEV1A
B.
siRNA UBC13
siRNA RAD18
+      +      +      +      +     
+
+
+
+ +
+
+
+
+
+ +
+
293T
Long 
Expo
Short 
Expo
(Ub)1-PCNA
PCNA 
Actin
Polyub
PCNA 
(Ub)1-PCNA
PCNA BMC Molecular Biology 2008, 9:24 http://www.biomedcentral.com/1471-2199/9/24
Page 7 of 11
(page number not for citation purposes)
PCNA ubiquitin laddering is not altered by the knockdown of MMS2 and UEV1a Figure 5
PCNA ubiquitin laddering is not altered by the knockdown of MMS2 and UEV1a. (A) Hela and (C) 293T cells were 
treated as in Figure 1 followed by immunoblotting for MMS2 and UEV1a (B) Hela and (D) 293T cells were transfected as 
described in figure 1. Seventy-two hours post-transfection, cells were irradiated with 30 J/m2 of UV and lysed 6 h later in boil-
ing SDS, diluted in lysis buffer, and subjected to immunoprecipitation with a PCNA antibody and immunoblotted for PCNA 
(upper panel) and Ub (lower panel). The controls in the immunoprecipitations were "B+L", in which lysates were incubated 
with beads but no PCNA antibody, and "1°+B" in which PCNA antibody was incubated with beads alone. Asterisks denote 
immunoglobulin heavy and light chains as detected in the immunoprecipitations.
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alternatively spliced isoforms including UEV1a
(CROC1A), KUA-UEV, and Croc1B which vary in their 5'
sequence [24,31,32]. Such UEVs may potentially comple-
ment hMMS2. However, based on structural studies
TSG101 is an unlikely candidate to complement hMMS2
as it does not bind with UBC13 and to date has not been
shown to catalyze K63 polyubiquitination [24]. UEV3 can
also be eliminated as its sequence is very similar to
TSG101 and it likely does not associate with UBC13
[29,31]. In addition, Thompson et al. show that KUA-UEV
is strictly localized to the cytoplasm [31], excluding the
protein from the site of DNA repair and thereby excluding
it as a functional substitute for MMS2. Furthermore, a
yeast two hybrid study eliminates CROC1b as a candidate
since it failed to show interaction with UBC13 [21].
hUEV1a would appear to be a strong candidate to comple-
ment MMS2 because it can bind to UBC13, localize to the
nucleus, and complement the Mms2 yeast mutant. It also
has greater than 90% amino acid sequence identity with
hMMS2 [25,31,32]. Therefore, we used siRNA to target
UEV1a along with hMMS2. However, the combined
knockdown of UEV1a and hMMS2 did not abrogate
PCNA polyubiquitination in human cells. This result is
consistent with two distinct cellular roles of hMMS2 (in
DNA repair) and UEV1a (in NF-κB activation) as previ-
ously shown by Anderson et al. and argues against a joint
or collaborative role in DDT [21].
Previous studies have clearly shown that the expression of
anti-sense MMS2 in human cells results in increased UV
induced mutagenesis. Our contention that MMS2 is dis-
pensible for PCNA ubiquitination leads to some obvious
questions concerning the role of MMS2 in DNA damage
tolerance in human cells. However, it is possible that the
function of MMS2 in human cells with respect to DNA
damage tolerance is one that is independent of PCNA
ubiquitination. An intriguing possibility is that it plays a
direct role in homologous recombination itself. In fact
this has recently been suggested in the case for its het-
erodimeric partner UBC13 and its E3 ligase partner
RAD18 [33,34]. Both proteins seem to be playing a direct
role in homologous recombination itself. While RAD18
seems to facilitate HR by suppressing NHEJ, cells deficient
in UBC13 are unable to recruit the key HR proteins RPA,
BRCA1, and Rad51 to sites of DNA damage. This occurs
due to a failure in a very early stage of HR-mediated repair
of DNA double strand breaks (DSBs) where UBC13 is
required to process DSBs into a competent HR substrate.
This may help explain why the PCNA-K164R mutant
DT40 cells are different in certain aspects from the ones of
cells deficient in RAD18 or UBC13, which implies that
some aspects of DNA damage tolerance are independent
of PCNA modification. Moreover, it suggests that PCNA
ubiquitination might be involved in additional processes
such as growth; a contention supported by the smaller size
and the sub-mendelian frequency at which homologous
PCNA K164R mutant mice are born [35]. Finally as shown
by Motegi et al. and Unk et al., the function of MMS2 in
PCNA ubiquitination might be linked to the one of
SHPRH, a recently discovered functional orthologue of
yeast RAD5 [14,15]. Certainly in yeast the ability of MMS2
and UBC13 to ubiquitinate PCNA largely depends on
PCNA ubiquitination decreases after RAD18 knockdown Figure 6
PCNA ubiquitination decreases after RAD18 knock-
down. A) 293T cells were transfected with 100 nM of either 
control siRNA, MMS2 and UEV1A siRNA or RAD18 siRNA 
followed by immunoblotting. B) Seventy-two hours post-
transfection, cells were subjected to immunoprecipitation 
with a PCNA antibody and immunoblotted for PCNA (upper 
panel) and Ub (lower panel). A PCNA immunoblot with 
darker and lighter exposure performed on protein lysates 
from the same samples used in the immunoprecipitations is 
also shown. Asterisks denote immunoglobulin heavy and light 
chains as detected in the immunoprecipitations.
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MMS2 null mouse emybronic stem show no overt disruption of PCNA polyubiquitination after UV irradiation Figure 7
MMS2 null mouse emybronic stem show no overt disruption of PCNA polyubiquitination after UV irradiation. 
(A) RT-PCR for MMS2 was performed as described in material and methods (B) Wild type and MMS2 null embryonic stem 
cells were lysed and subjected to immunoblotting with anti-Mms2/Uev1a antibody. (C) Confluent plates of wild type and 
MMS2 null embryonic stem cells were split 1:4 on Day 1. On Day 2 media was replaced and followed by UV irradiation with 
either 0 or 30 J/m2 on Day 3. Cells were harvested 6 hours post-treatment and subjected to immunoblotting with an anti-
PCNA antibody. (D) Wild type and MMS2 null embryonic stem cells were transfected with Uev1a and lysed 72 hours later fol-
lowed by immunoblotting with anti-Mms2/Uev1a antibody. (E) MMS2-/- cells were transfected with siRNA targeting mouse 
UEV1a. 72 hours post transfection cells were UV irradiated, lysed and subjected to immunoblotting using an anti-PCNA anti-
body.
M
m
s
2
 
+
/
+
M
m
s
2
 
-
/
-
Mms2
 B.
Actin
Mms2 -/-
Mms2 +/+
UV 30 J/m2
 C.
Long 
Expo
Short 
Expo
(Ub)1-PCNA
PCNA 
(Ub)1-PCNA
PCNA 
(Ub)2-PCNA
Polyub
PCNA 
Actin
+ +
+
+
+
+
M   +/+  -/-
400
200
400
200
mMms2
E-actin
A.
D.
(Ub)2-PCNA
(Ub)3-PCNA
PCNA 
Actin
(Ub)1-PCNA
PCNA 
(Ub)1-PCNA
Mms2-/-
Mms2+/+
Uev1a RNAi
UV 30 J/m2
Control RNAi
+ +
+ + + +
+ +
+ + + +
+ +
+ + + +
+ +
Long 
Expo
Short 
Expo
Actin
Mms2/
Uev1a
Mms2-/-
Mms2+/+
Uev1a RNAi
Control RNAi +
+ +
+
+
+
+
+
E.BMC Molecular Biology 2008, 9:24 http://www.biomedcentral.com/1471-2199/9/24
Page 10 of 11
(page number not for citation purposes)
RAD5. Therefore, this distinct possibility cannot be
excluded from occurring in human cells with MMS2 and
SHPRH.
It is possible that complexes other than the heteromeric
couple of UBC13/UEV may be able to complement the
loss of hMMS2 (an example of such a complex is Np14/
UFD1 which is also able to catalyze the formation of K63-
polyubiquitin chains [36]) but there exists the intriguing
possibility that a previously unreported MMS2 variant
(herein designated hMMS2v) functionally complements
MMS2 in the assembly of polyubiquitin chains on the
PCNA of cells sustaining DNA damage. We have prelimi-
nary data indicating that such a variant is present at low
levels in HEK 293 cells (Brun et al., unpublished). If
response to DNA damage is compartmentalized then even
low levels of the hMMS2 variant could potentially com-
pensate for the loss of MMS2. However, whether this var-
iant form is resistant to the siRNA used in this paper or if
it is absent in the mouse embryonic knock cells remains
to be determined. Further investigations will be required
to determine the ubiquity of hMMS2v, its role in DNA
repair, whether it contains UBC13 binding domain, and
whether siRNA targeting of both hMMS2 and hMMS2v
will fully abrogate PCNA ubiquitination.
Conclusion
In a previous study we demonstrated that K63-linked
polyubiquitination guards against environmental muta-
genesis and specifically that the target of this ubiquitina-
tion PCNA is dependant on RAD18 and UBC13 [12]. It
would be reasonable to assume that as the heteromeric
partner of UBC13, MMS2 would be directly involved in
PCNA polyubiquitination, but the data reported herein
are not consistent with this prediction. On the contrary
MMS2 and UEV1A seem to serve redundant roles in PCNA
polyubiquitination suggesting the existence of an alterna-
tive MMS2 variant or novel E2 that can complement the
loss of MMS2. Although our work does not identify the
redundant protein, we believe the redundancy is in itself
an unexpected and important finding that will spur fur-
ther investigation.
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